» Articles » PMID: 37047804

Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Apr 13
PMID 37047804
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is a very rare genetic disease characterized by progressive heterotopic ossification (HO) of soft tissues, leading to immobility and premature death. FOP is caused by a mutation in the Activin receptor Type 1 (ACVR1) gene, resulting in altered responsiveness to Activin-A. We recently revealed that Activin-A induces fewer, but larger and more active, osteoclasts regardless of the presence of the mutated ACVR1 receptor. The underlying mechanism of Activin-A-induced changes in osteoclastogenesis at the gene expression level remains unknown. Transcriptomic changes induced by Activin-A during osteoclast formation from healthy controls and patient-derived CD14-positive monocytes were studied using RNA sequencing. CD14-positive monocytes from six FOP patients and six age- and sex-matched healthy controls were differentiated into osteoclasts in the absence or presence of Activin-A. RNA samples were isolated after 14 days of culturing and analyzed by RNA sequencing. Non-supervised principal component analysis (PCA) showed that samples from the same culture conditions (e.g., without or with Activin-A) tended to cluster, indicating that the variability induced by Activin-A treatment was larger than the variability between the control and FOP samples. RNA sequencing analysis revealed 1480 differentially expressed genes induced by Activin-A in healthy control and FOP osteoclasts with (adj) < 0.01 and a Log2 fold change of ≥±2. Pathway and gene ontology enrichment analysis revealed several significantly enriched pathways for genes upregulated by Activin-A that could be linked to the differentiation or function of osteoclasts, cell fusion or inflammation. Our data showed that Activin-A has a substantial effect on gene expression during osteoclast formation and that this effect occurred regardless of the presence of the mutated ACVR1 receptor causing FOP.

Citing Articles

Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.

Diolintzi A, Pervin M, Hsiao E Biomolecules. 2024; 14(3).

PMID: 38540775 PMC: 10967946. DOI: 10.3390/biom14030357.


Transcriptional reprogramming during human osteoclast differentiation identifies regulators of osteoclast activity.

Hansen M, Madsen K, Price M, Soe K, Omata Y, Zaiss M Bone Res. 2024; 12(1):5.

PMID: 38263167 PMC: 10806178. DOI: 10.1038/s41413-023-00312-6.

References
1.
Wang X, Ding Z, Lin J, Guo Z, Mehta J . LOX-1 in macrophage migration in response to ox-LDL and the involvement of calpains. Biochem Biophys Res Commun. 2015; 467(1):135-9. DOI: 10.1016/j.bbrc.2015.09.100. View

2.
Kang D, Choi M, Chang S, Lee M, Lee D, Choi K . Vascular Proteomics Reveal Novel Proteins Involved in SMC Phenotypic Change: OLR1 as a SMC Receptor Regulating Proliferation and Inflammatory Response. PLoS One. 2015; 10(8):e0133845. PMC: 4548952. DOI: 10.1371/journal.pone.0133845. View

3.
Jones K, Mansell A, Patella S, Scott B, Hedger M, de Kretser D . Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci U S A. 2007; 104(41):16239-44. PMC: 2042191. DOI: 10.1073/pnas.0705971104. View

4.
Pignolo R, Shore E, Kaplan F . Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011; 6:80. PMC: 3253727. DOI: 10.1186/1750-1172-6-80. View

5.
Song R, Gu J, Liu X, Zhu J, Wang Q, Gao Q . Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone. Int J Mol Med. 2014; 34(3):856-62. DOI: 10.3892/ijmm.2014.1846. View